Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 430,374
  • Shares Outstanding, K 102,470
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,070 K
  • 36-Month Beta 1.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.12

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.77 +51.62%
on 11/13/17
4.51 -6.87%
on 12/01/17
+1.33 (+46.34%)
since 11/10/17
3-Month
2.38 +76.47%
on 09/26/17
4.51 -6.87%
on 12/01/17
+1.64 (+64.06%)
since 09/11/17
52-Week
1.01 +315.84%
on 12/30/16
4.51 -6.87%
on 12/01/17
+3.02 (+255.93%)
since 12/09/16

Most Recent Stories

More News
Biotech's Flying Under The Radar

Biotech investors spend a ton of time considering what the cure for cancer could be or the next invention that could eliminate a rare disease. It's difficult to keep track of the advancements and developments...

ESPR : 57.13 (+0.28%)
AEZS : 2.20 (-1.35%)
PPCB : 0.1988 (-65.72%)
GERN : 1.99 (-1.97%)
CPRX : 4.20 (+5.00%)
Analysis: Positioning to Benefit within Office Depot, ImmunoGen, Cedar Realty Trust, Carbo Ceramics, Consolidated Communications, and Catalyst Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Office Depot, Inc. (NASDAQ:ODP),...

CDR : 6.12 (+0.66%)
CRR : 10.14 (+2.22%)
IMGN : 6.18 (-0.32%)
ODP : 3.38 (+3.36%)
CNSL : 13.28 (+7.70%)
CPRX : 4.20 (+5.00%)
Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

CTMX : 21.11 (+2.68%)
REGN : 381.32 (+0.14%)
CPRX : 4.20 (+5.00%)
ALKS : 52.16 (-1.36%)
AMGN : 176.83 (+0.81%)
BIIB : 328.03 (+0.69%)
Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock

CORAL GABLES, FL--(Marketwired - Nov 28, 2017) - Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) today announced the pricing of its previously announced underwritten public offering. The Company announced...

CPRX : 4.20 (+5.00%)
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

LGND : 135.06 (+0.27%)
SCMP : 16.25 (+1.56%)
BMRN : 88.11 (+7.46%)
CPRX : 4.20 (+5.00%)
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announced today that it has commenced an underwritten public offering of 11 million shares of its common stock. Catalyst also intends to grant the underwriters...

CPRX : 4.20 (+5.00%)
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse(R) in Patients with Lambert-Eaton Myasthenic Syndrome

-- Treatment with Firdapse Achieved Statistical Significance for Co-Primary Endpoints and Secondary Endpoint --

CPRX : 4.20 (+5.00%)
Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.

LGND : 135.06 (+0.27%)
SCMP : 16.25 (+1.56%)
BMRN : 88.11 (+7.46%)
CPRX : 4.20 (+5.00%)
Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse(R) in Ambulatory Patients with Spinal Muscular Atrophy (SMA)

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...

CPRX : 4.20 (+5.00%)
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan

If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com shifts focus on Catalyst...

SUPN : 37.95 (-0.52%)
AGN : 172.76 (+2.96%)
CPRX : 4.20 (+5.00%)
FLXN : 24.91 (-2.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for...

See More

Key Turning Points

2nd Resistance Point 4.36
1st Resistance Point 4.28
Last Price 4.20
1st Support Level 4.07
2nd Support Level 3.94

See More

52-Week High 4.51
Last Price 4.20
Fibonacci 61.8% 3.17
Fibonacci 50% 2.76
Fibonacci 38.2% 2.35
52-Week Low 1.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.